Department of Biology, Massachusetts Institute of Technology, Cambridge, USA.
MIT Koch Institute for Integrative Cancer Research, Cambridge, USA.
Blood Cancer J. 2023 Jun 8;13(1):92. doi: 10.1038/s41408-023-00863-1.
Whole chromosome losses resulting in near-haploid karyotypes are found in a rare subgroup of treatment-refractory acute lymphoblastic leukemia. To systematically dissect the unique physiology and uncover susceptibilities that can be exploited in near-haploid leukemia, we leveraged single-cell RNA-Seq and computational inference of cell cycle stages to pinpoint key differences between near-haploid and diploid leukemia cells. Combining cell cycle stage-specific differential expression with gene essentiality scores from a genome-wide CRISPR-Cas9-mediated knockout screen, we identified the homologous recombination pathway component RAD51B as an essential gene in near-haploid leukemia. DNA damage analyses revealed significantly increased sensitivity of RAD51-mediated repair to RAD51B loss in the G2/M stage of near-haploid cells, suggesting a unique role of RAD51B in the homologous recombination pathway. Elevated G2/M and G1/S checkpoint signaling was part of a RAD51B signature expression program in response to chemotherapy in a xenograft model of human near-haploid B-ALL, and RAD51B and its associated programs were overexpressed in a large panel of near-haploid B-ALL patients. These data highlight a unique genetic dependency on DNA repair machinery in near-haploid leukemia and demarcate RAD51B as a promising candidate for targeted therapy in this treatment-resistant disease.
全染色体缺失导致近单体核型的情况存在于一组罕见的治疗抵抗性急性淋巴细胞白血病亚组中。为了系统地剖析近单体白血病的独特生理学,并揭示可被利用的易感性,我们利用单细胞 RNA-Seq 和细胞周期阶段的计算推断,来确定近单体和二倍体白血病细胞之间的关键差异。将细胞周期阶段特异性差异表达与来自全基因组 CRISPR-Cas9 介导的敲除筛选的基因必需性评分相结合,我们确定同源重组途径组件 RAD51B 是近单体白血病中的必需基因。DNA 损伤分析显示,在近单体细胞的 G2/M 期,RAD51 介导的修复对 RAD51B 缺失的敏感性显著增加,这表明 RAD51B 在同源重组途径中具有独特的作用。在人类近单体 B-ALL 的异种移植模型中,RAD51B 及其相关程序作为对化疗的反应的一部分,上调了 G2/M 和 G1/S 检查点信号,并且在大量近单体 B-ALL 患者中过度表达。这些数据突出了近单体白血病中对 DNA 修复机制的独特遗传依赖性,并将 RAD51B 确定为这种治疗抵抗性疾病的靶向治疗有希望的候选物。